The Globe and Mail reports in its Wednesday edition that BTIG analyst Thomas Shrader began coverage on IMV with a "buy" rating and $8 target. The Globe's David Leeder writes that analysts on average target the shares at $10.22. Mr. Shrader says IMV's DPX technology "flies in the face of much of modern immunology." He "remains curious" about its early results which "leave little doubt" about its potential. Mr. Shrader says in a note: "IMV is a clinical-stage biotechnology company focused on developing the DPX technology to generate powerful and prolonged anti-tumor responses to both solid and hematological tumor patients. The lead program is focused on the validated TAA survivin applied to OC [ovarian cancer] and DLBCL [diffuse large B-cell lymphoma]. Data to date are from smallish trials somewhat clouded by combination regimen but clearly suggest overall anti-tumor efficacy. Importantly, OC monotherapy data are due in early 2020 that could both de-risk the current clinical programs and support the DPX platform for the delivery of other TAAs and neoantigens in anti-tumor therapeutics." Mr. Shrader finds it "reassuring" that Merck & Co. has forged a partnership in both DLBC and the solid tumour basket trial.